In contrast, the inhibition of Egr1 expression in the AD hippocampus reduces Aβ pathology, improves cognitive performance, and reduces tau phosphorylation; thus, Egr1 has been recognized as a potential therapeutic agent for AD [37]. The gene discussed is MAPT; the disease is Alzheimer disease.